RMIM20 Sponsor Exhibit
In 2012, Bristol Myers Squibb and Pfizer launched ELIQUIS in Canada, an oral anticoagulant discovered by Bristol Myers Squibb. This global alliance combines Bristol Myers Squibb's deep and long-standing commitment to cardiovascular disease that began over 60 years ago with Pfizer’s global scale and expertise in this field.
If you would like more information on ELIQUIS , please contact Xanthe Blundon via email here.
BMS website click here
Pfizer website click here
Atypical Hemolytic Uremic Syndrome (aHUS)
In atypical Hemolytic Uremic Syndrome (atypical HUS), uncontrolled complement activation leads to systemic thrombotic microangiopathy (TMA), causing progressive damage to vital organs and premature death. Click here to learn more.
The catastrophic consequences of atypical HUS make RAPID DIAGNOSIS and CLINICAL INTERVENTION CRITICAL. Click here to view a tool to support differential diagnosis tool in aHUS.
SOLIRIS® (eculizumab for injection) is indicated for the treatment of patients with atypical hemolytic uremic syndrome (atypical HUS) to reduce complement-mediated thrombotic microangiopathy. SOLIRIS is not indicated for the treatment of patients with Shiga toxin-producing E. coli related hemolytic uremic syndrome (STEC-HUS). Click here to learn more.
Paroxysmal Nocturnal Hemoglobinuria (PHN)
Early diagnosis is essential for improved patient management and prognosis in PNH. Click here for additional information.
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive and life-threatening disease associated with morbidities and premature mortality. Click here for additional information.
Hemolytic Anemia algorithm - Click here to view a tool with a practical approach to patients with anemia and hemolysis.
How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. Click here to view.